UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

EGFR inhibition for recurrent or metastatic HNSCC

The lancet oncology, 2015-05, Vol.16 (5), p.488-489

Argiris, Athanassios

2015

Volltextzugriff (PDF)

Current status and future directions in induction chemotherapy for head and neck cancer

Critical reviews in oncology/hematology, 2013-10, Vol.88 (1), p.57-74

Argiris, Athanassios

2013

Volltextzugriff (PDF)

Head and neck cancer

The Lancet (British edition), 2008-05, Vol.371 (9625), p.1695-1709

2008

Volltextzugriff (PDF)

Laryngeal Preservation Strategies in Locally Advanced Laryngeal and Hypopharyngeal Cancers

Frontiers in oncology, 2019-05, Vol.9, p.419-419

2019

Volltextzugriff (PDF)

Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2010-01, Vol.28 (1), p.56-62

2010

Volltextzugriff (PDF)

Combining Radiation and Immune Checkpoint Blockade in the Treatment of Head and Neck Squamous Cell Carcinoma

Frontiers in oncology, 2019-03, Vol.9, p.122

2019

Volltextzugriff (PDF)

Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Frontiers in oncology, 2017-05, Vol.7, p.72-72

2017

Volltextzugriff (PDF)

Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial

Journal of clinical oncology, 2013-04, Vol.31 (11), p.1405-1414

2013

Volltextzugriff (PDF)

Phase I Dendritic Cell p53 Peptide Vaccine for Head and Neck Cancer

Clinical cancer research, 2014-05, Vol.20 (9), p.2433-2444

2014

Volltextzugriff (PDF)

Editorial: Advances in the Systemic Therapy and Combined Modality Approaches for Head and Neck Cancer

Frontiers in oncology, 2019-11, Vol.9, p.1190-1190

2019

Volltextzugriff (PDF)

Emerging aspects of nanotoxicology in health and disease: From agriculture and food sector to cancer therapeutics

Food and chemical toxicology, 2016-05, Vol.91 (May), p.42-57

2016

Volltextzugriff (PDF)

Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer

Clinical cancer research, 2010-12, Vol.16 (23), p.5900-5907

2010

Volltextzugriff (PDF)

Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas

JAMA : the journal of the American Medical Association, 2007-07, Vol.298 (1), p.70

2007

Volltextzugriff (PDF)

Preoperative Immunotherapy in the Multidisciplinary Management of Oral Cavity Cancer

Frontiers in oncology, 2021-07, Vol.11, p.682075-682075

2021

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies

Clinical cancer research, 2007-06, Vol.13 (12), p.3605-3610

2007

Volltextzugriff (PDF)

Phase II Trial of Pemetrexed and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer

Journal of clinical oncology, 2011-03, Vol.29 (9), p.1140-1145

2011

Volltextzugriff (PDF)

Induction Docetaxel, Cisplatin, and Cetuximab Followed by Concurrent Radiotherapy, Cisplatin, and Cetuximab and Maintenance Cetuximab in Patients With Locally Advanced Head and Neck Cancer

Journal of clinical oncology, 2010-12, Vol.28 (36), p.5294-5300

2010

Volltextzugriff (PDF)

Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment Effect

Frontiers in oncology, 2020-12, Vol.10, p.566315-566315

2020

Volltextzugriff (PDF)

Tumor Epidermal Growth Factor Receptor and EGFR PY1068 Are Independent Prognostic Indicators for Head and Neck Squamous Cell Carcinoma

Clinical cancer research, 2012-04, Vol.18 (8), p.2278-2289

2012

Volltextzugriff (PDF)

Stereotactic Body Radiotherapy for Recurrent Squamous Cell Carcinoma of the Head and Neck: Results of a Phase I Dose-Escalation Trial

International journal of radiation oncology, biology, physics, 2009-12, Vol.75 (5), p.1493-1500

2009

Volltextzugriff (PDF)

The impact of tumor volume and radiotherapy dose on outcome in previously irradiated recurrent squamous cell carcinoma of the head and neck treated with stereotactic body radiation therapy

American journal of clinical oncology, 2011-08, Vol.34 (4), p.372-379

2011

Volltextzugriff (PDF)

Neoadjuvant nivolumab (N) plus cisplatin (C)/pemetrexed (P) or cisplatin /gemcitabine (G) in resectable NSCLC

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.9051-9051

2020

Volltextzugriff (PDF)

Erlotinib, Erlotinib-Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer

Clinical cancer research, 2014-06, Vol.20 (12), p.3289-3298

2014

Volltextzugriff (PDF)

Predictive capacity of immune‐related adverse events and cytokine profiling in neoadjuvant immune checkpoint inhibitor trials for head and neck squamous cell carcinoma

Cancer medicine (Malden, MA), 2024-06, Vol.13 (11), p.e7370-n/a

2024

Volltextzugriff (PDF)

1 – 25 von 207

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(200)
Mit Volltextzugriff
(191)

Publikationsform

Artikel
(203)
Buchkapitel
(4)

Sprache

Englisch
(207)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(124)
Science & Technology
(124)
Humans
(121)
Oncology
(101)
Female
(73)
Male
(73)
Middle Aged
(67)
Aged
(62)
Biological And Medical Sciences
(51)
Medical Sciences
(51)
Adult
(50)
Head And Neck Neoplasms - Drug Therapy
(48)
Tumors
(42)
Treatment Outcome
(39)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(38)
Aged, 80 And Over
(32)
Otorhinolaryngology
(32)
Head And Neck Neoplasms - Pathology
(31)
Carcinoma, Squamous Cell - Drug Therapy
(29)
Chemotherapy
(29)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

EGFR inhibition for recurrent or metastatic HNSCC

Current status and future directions in induction chemotherapy for head and neck cancer

Head and neck cancer

Laryngeal Preservation Strategies in Locally Advanced Laryngeal and Hypopharyngeal Cancers

Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer

Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651

Combining Radiation and Immune Checkpoint Blockade in the Treatment of Head and Neck Squamous Cell Carcinoma

Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial

Phase I Dendritic Cell p53 Peptide Vaccine for Head and Neck Cancer

Editorial: Advances in the Systemic Therapy and Combined Modality Approaches for Head and Neck Cancer

Emerging aspects of nanotoxicology in health and disease: From agriculture and food sector to cancer therapeutics

Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer

Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas

Preoperative Immunotherapy in the Multidisciplinary Management of Oral Cavity Cancer

Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies

Phase II Trial of Pemetrexed and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer

Induction Docetaxel, Cisplatin, and Cetuximab Followed by Concurrent Radiotherapy, Cisplatin, and Cetuximab and Maintenance Cetuximab in Patients With Locally Advanced Head and Neck Cancer

Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment Effect

Tumor Epidermal Growth Factor Receptor and EGFR PY1068 Are Independent Prognostic Indicators for Head and Neck Squamous Cell Carcinoma

Stereotactic Body Radiotherapy for Recurrent Squamous Cell Carcinoma of the Head and Neck: Results of a Phase I Dose-Escalation Trial

The impact of tumor volume and radiotherapy dose on outcome in previously irradiated recurrent squamous cell carcinoma of the head and neck treated with stereotactic body radiation therapy

Neoadjuvant nivolumab (N) plus cisplatin (C)/pemetrexed (P) or cisplatin /gemcitabine (G) in resectable NSCLC

Erlotinib, Erlotinib-Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer

Predictive capacity of immune‐related adverse events and cytokine profiling in neoadjuvant immune checkpoint inhibitor trials for head and neck squamous cell carcinoma

Suchergebnisse filtern